| Virksomhedsstatus | | UNDER FRIVILLIG LIKVIDATION. |
| Sidst opdateret den 16.08.2022 og
angivet som gældende fra 15.08.2022 (622
dage). |
| Historik | Start | Stop |
|---|
| UNDER FRIVILLIG LIKVIDATION | 15.08.2022 | |
| NORMAL | 09.09.2004 | 14.08.2022 |
| Branche | | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
| Sidst opdateret den 24.12.2007 og
angivet som gældende fra 01.01.2008 (5962
dage). |
| Historik | Start | Stop |
|---|
| Forskning og eksperimentel udvikling indenfor bioteknologi (721100) | 01.01.2008 | |
| Forskning og udvikling inden for naturvidenskab og teknik (731000) | 06.03.2006 | 31.12.2007 |
| Udvikling af standardsoftware (722100) | 20.09.2004 | 05.03.2006 |
| Uoplyst (980000) | 09.09.2004 | 19.09.2004 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 05.01.2009 (5592
dage). |
Ingen historik.
| Historik | Start | Stop |
|---|
| nla@medical-prognosis.com | 30.03.2016 | 19.02.2020 |
| steen@medical-prognosis.com | 06.03.2006 | 29.03.2016 |
Ingen nuværende registrering.
Ingen nuværende registrering.
Ingen historik.
| Navne | | Allarity Therapeutics A/S. |
| Sidst opdateret den 07.10.2020 og
angivet som gældende fra 07.10.2020 (1299
dage). |
| Historik | Start | Stop |
|---|
| Allarity Therapeutics A/S | 07.10.2020 | |
| ONCOLOGY VENTURE A/S | 30.05.2018 | 06.10.2020 |
| MEDICAL PROGNOSIS INSTITUTE A/S | 07.11.2008 | 29.05.2018 |
| MEDICAL PROGNOSIS INSTITUTE ApS | 09.09.2004 | 06.11.2008 |
| Binavne | | Allarity A/S. |
| Sidst opdateret den 07.10.2020 og
angivet som gældende fra 07.10.2020 (1299
dage). |
| Historik | Start | Stop |
|---|
| Allarity A/S | 07.10.2020 | |
| Medical Prognosis Institute A/S | 07.10.2020 | |
| Oncology Venture A/S | 07.10.2020 | |
| MEDICAL PROGNOSIS INSTITUTE A/S | 21.08.2018 | 06.10.2020 |
| Tegningsregel | | Virksomheden tegnes af en likvidator. |
| Sidst opdateret den 16.08.2022 og
angivet som gældende fra 15.08.2022 (622
dage). |
| Fortolkning
(1 tegningsmulighed)
| | en likvidator |
| Historik | Start | Stop |
|---|
| Virksomheden tegnes af en likvidator | 15.08.2022 | |
| Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af en direktør i forening med to bestyrelsesmedlemmer eller af den samlede bestyrelse | 26.02.2015 | 14.08.2022 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Pricewaterhousecoopers
Revisionsvirksomhedens CVR-nr.:33771231
Beskrivelse af revisor:State Authorized Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor's responsibilities for the audit of the financial statements” section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Allarity Therapeutics A/S (In liquidation) for the financial year 1 January - 31 December 2022, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The financial statements are prepared under the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2022 and of the results of the company's operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on management's review
Management is responsible for management's review.
Our opinion on the financial statements døs not cover management's review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration